Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Ankylosing Spondylitis (AS) Market Outlook

Thelansis’s “Ankylosing Spondylitis (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ankylosing Spondylitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ankylosing Spondylitis (AS) Overview

Ankylosing spondylitis (AS) is a type of arthritis primarily impacting the spine, potentially affecting other joints as well. It results in inflammation of the spinal vertebrae, leading to persistent and severe pain. In advanced stages, this inflammation can cause ankylosis, which is the formation of new bone in the spine, resulting in spine sections becoming fused and immobile. Additionally, AS can bring about inflammation, pain, and stiffness in various body parts, including the shoulders, hips, ribs, heels, and small joints of the hands and feet. On rare occasions, it can involve the eyes, known as iritis or uveitis, and affect the lungs and heart. A distinctive characteristic of ankylosing spondylitis is its impact on the sacroiliac (SI) joints, located at the spine's base, where it connects with the pelvis. Although symptoms generally manifest in late adolescence or early adulthood, typically between the ages of 17 and 45, they can also emerge in childhood or later in life. Risk factors contributing to the development of AS encompass testing positive for the HLA-B27 marker, having a family history of the condition, and experiencing frequent gastrointestinal infections. Unlike other types of arthritis and rheumatic diseases, AS tends to affect younger individuals, usually those aged between 17 and 45. However, it can affect children and older individuals as well. The severity of AS varies significantly among individuals, with not everyone experiencing the most severe complications or spinal fusion. Some may endure occasional back pain and discomfort, while others may suffer from prolonged, severe pain and stiffness affecting various body parts. AS can be debilitating and, in some instances, result in disability.

• Although no known cure for AS exists, treatments and medications are available to alleviate symptoms and manage pain. It's estimated that at least 1.7 million adults in the United States have AS, while 3.2 million have some form of axial spondyloarthritis.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: